Clinical classification of pulmonary hypertension

Clinics in Chest Medicine

Volumn 22, Issue 3, 2001, Pages 385-391

  Fishman, Alfred P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPSY; CLINICAL FEATURE; DISEASE CLASSIFICATION; HUMAN; NOMENCLATURE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGISTER; REVIEW; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 0034804681     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(05)70278-1     Document Type: Article

References (60)

1. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
2. Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications
3. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
4. Vasodilator therapy for primary pulmonary hypertension in children
5. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
6. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
7. Effect of long-term oxygen treatment at home in children with pulmonary vascular disease
8. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn
9. Modifications of techniques and early results of pulmonary thromboendarterectomy for chronic pulmonary embolism
10. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease
11. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutants in bone morphogenetic protein receptor-II gene
12. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary veno-occlusive disease
13. Clinical primary pulmonary hypertension. Three pathologic types
14. Pulmonary capillary hemangiomatosis: A clinicopathologic review
15. Dietary pulmonary hypertension
16. Introduction to the National Registry on Primary Pulmonary Hypertension
17. Aminorex to fen/phen. An epidemic foretold
18. Primary pulmonary hypertension: Natural history and the importance of thrombosis
19. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension
20. Pulmonary hypertension, "aplexogenic pulmonary arteriopathy" and the appetite-depressant drug aminorex: Post or prompter?
21. Aminorex pulmonary hypertension
22. The pathology of hypertensive pulmonary vascular disease. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects
23. Pulmonary vascular disorders in portal hypertension
24. Treatment of pulmonary hypertension with the continuous infusion of a prostaglandin analogue iloprost
25. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension
26. Treatments for severe pulmonary hypertension
27. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis
28. The treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin)
29. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study
30. Pulmonary thromboendarterectomy
31. Worldwide thoracic organ transplantation: A report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation
32. Continuous intravenous infusion of epoprostenol for the treatment of porto-pulmonary hypertension
33. Inhaled endothelin-1 antagonist attenuates hypoxic-induced pulmonary hypertension in rats
34. Reduction in pulmonary vascular resistance with long-term epoprostenol prostacyclin therapy in primary hypertension
35. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series
36. Lung transplantation: A decade of experience
37. Mapping of familial primary pulmonary hypertension locus (PPHI) to chromosome 2q31- 32
38. Chronic thromboembolic pulmonary hypertension: Clinical picture and surgical treatment
39. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial
40. Pulmonary thromboembolic disease
41. Inhaled nitric oxide causes selective pulmonary vasodilation in patients with pulmonary hypertension
42. The histopathology of primary pulmonary hypertension
43. Heart-lung transplantation successful therapy for patients with pulmonary vascular disease
44. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
45. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
46. Primary pulmonary hypertension
47. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension
48. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial
49. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)
50. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment
51. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
52. Prostacyclin for HIV-associated pulmonary hypertension
53. Pulmonary venoocclusive disease: CT findings in eight patients
54. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease
55. Pulmonary veno-occlusive disease
56. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease
57. Heart-lung transplantation for primary pulmonary hypertension